Advertisement
Screener

X4 PHARMACEUTICALS, INC (XFOR) Increase (Decrease) in Accounts Payable

2.8 / 5 stars · 68/120 Roast Me

X4 PHARMACEUTICALS, INC Increase (Decrease) in Accounts Payable

X4 PHARMACEUTICALS, INC (XFOR) reported Increase (Decrease) in Accounts Payable of -$1.76 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.

Financial Statements › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-06

  • X4 PHARMACEUTICALS, INC increase (decrease) in accounts payable for the quarter ending 2026-06-30 was -$1.14M.
  • X4 PHARMACEUTICALS, INC increase (decrease) in accounts payable for the quarter ending 2026-03-31 was -$624.00K, a 125.20% decline year-over-year.
  • X4 PHARMACEUTICALS, INC increase (decrease) in accounts payable for the quarter ending 2025-12-31 was $642.00K, a 723.08% increase year-over-year.
  • X4 PHARMACEUTICALS, INC increase (decrease) in accounts payable for the quarter ending 2025-09-30 was -$2.65M, a 557.59% decline year-over-year.
  • X4 PHARMACEUTICALS, INC increase (decrease) in accounts payable for fiscal 2025 was -$2.98M.
  • X4 PHARMACEUTICALS, INC increase (decrease) in accounts payable for fiscal 2024 was -$286.00K, a 123.18% decline from fiscal 2023.
  • X4 PHARMACEUTICALS, INC increase (decrease) in accounts payable for fiscal 2023 was $1.23M, a 63.97% decline from fiscal 2022.
  • X4 PHARMACEUTICALS, INC increase (decrease) in accounts payable for fiscal 2022 was $3.42M, a 193.74% increase from fiscal 2021.
Period endIncrease (Decrease) in Accounts Payable 3 monthIncrease (Decrease) in Accounts Payable 3 month as first filedIncrease (Decrease) in Accounts Payable 6 monthIncrease (Decrease) in Accounts Payable 6 month as first filedIncrease (Decrease) in Accounts Payable 9 monthIncrease (Decrease) in Accounts Payable 9 month as first filedIncrease (Decrease) in Accounts Payable 12 monthIncrease (Decrease) in Accounts Payable 12 month as first filed
2026-06-30-$1.14M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06
-$1.76M
10-Q · filed 2026-08-06
-$1.12M
derived: sum of 3 quarters · filed 2026-08-06
-$3.78M
derived: sum of 4 quarters · filed 2026-08-06
2026-03-31-$624.00K
10-Q · filed 2026-05-06
$18.00K
derived: sum of 2 quarters · filed 2026-05-06
-$2.64M
derived: sum of 3 quarters · filed 2026-05-06
-$6.08M
derived: sum of 4 quarters · filed 2026-08-06
2025-12-31$642.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17
-$2.01M
derived: sum of 2 quarters · filed 2026-03-17
-$5.46M
derived: sum of 3 quarters · filed 2026-08-06
-$2.98M
10-K · filed 2026-03-17
2025-09-30-$2.65M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05
-$6.10M
derived: sum of 2 quarters · filed 2026-08-06
-$3.62M
10-Q · filed 2025-11-05
-$3.54M
derived: sum of 4 quarters · filed 2026-08-06
2025-06-30-$3.44M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06
-$967.00K
10-Q · filed 2026-08-06
-$889.00K
derived: sum of 3 quarters · filed 2026-08-06
-$309.00K
derived: sum of 4 quarters · filed 2026-08-06
2025-03-31$2.48M
10-Q · filed 2026-05-06
$2.55M
derived: sum of 2 quarters · filed 2026-05-06
$3.13M
derived: sum of 3 quarters · filed 2026-05-06
$2.19M
derived: sum of 4 quarters · filed 2026-05-06
2024-12-31$78.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17
$658.00K
derived: sum of 2 quarters · filed 2026-03-17
-$290.00K
derived: sum of 3 quarters · filed 2026-03-17
-$286.00K
10-K · filed 2026-03-17
2024-09-30$580.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05
-$368.00K
derived: sum of 2 quarters · filed 2025-11-05
-$364.00K
10-Q · filed 2025-11-05
$444.00K
derived: sum of 4 quarters · filed 2026-03-17
2024-06-30-$948.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08
-$944.00K
10-Q · filed 2025-08-08
-$136.00K
derived: sum of 3 quarters · filed 2026-03-17
$3.10M
derived: sum of 4 quarters · filed 2026-03-17
2024-03-31$4.00K
10-Q · filed 2025-05-01
$812.00K
derived: sum of 2 quarters · filed 2026-03-17
$4.05M
derived: sum of 3 quarters · filed 2026-03-17
$2.95M
derived: sum of 4 quarters · filed 2026-03-17
2023-12-31$808.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17
$4.05M
derived: sum of 2 quarters · filed 2026-03-17
$2.95M
derived: sum of 3 quarters · filed 2026-03-17
$1.23M
10-K · filed 2026-03-17
2023-09-30$3.24M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13
$2.14M
derived: sum of 2 quarters · filed 2024-11-13
$426.00K
10-Q · filed 2024-11-13
$4.33M
derived: sum of 4 quarters · filed 2025-03-26
2023-06-30-$1.10M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08
-$2.81M
10-Q · filed 2024-08-08
$1.09M
derived: sum of 3 quarters · filed 2025-03-26
$1.22M
derived: sum of 4 quarters · filed 2025-03-26
2023-03-31-$1.71M
10-Q · filed 2024-05-07
$2.19M
derived: sum of 2 quarters · filed 2025-03-26
$2.32M
derived: sum of 3 quarters · filed 2025-03-26
$2.42M
derived: sum of 4 quarters · filed 2025-03-26
2022-12-31$3.91M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-26
$4.03M
derived: sum of 2 quarters · filed 2025-03-26
$4.14M
derived: sum of 3 quarters · filed 2025-03-26
$3.42M
10-K · filed 2025-03-26
2022-09-30$124.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09
$232.00K
derived: sum of 2 quarters · filed 2023-11-09
-$481.00K
10-Q · filed 2023-11-09
$1.38M
derived: sum of 4 quarters · filed 2024-03-21
2022-06-30$108.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10
-$605.00K
10-Q · filed 2023-08-10
$1.26M
derived: sum of 3 quarters · filed 2024-03-21
$1.15M
derived: sum of 4 quarters · filed 2024-03-21
2022-03-31-$713.00K
10-Q · filed 2023-05-04
$1.15M
derived: sum of 2 quarters · filed 2024-03-21
$1.04M
derived: sum of 3 quarters · filed 2024-03-21
$476.00K
derived: sum of 4 quarters · filed 2024-03-21
2021-12-31$1.86M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21
$1.76M
derived: sum of 2 quarters · filed 2024-03-21
$1.19M
derived: sum of 3 quarters · filed 2024-03-21
$1.17M
10-K · filed 2024-03-21
2021-09-30-$103.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03
-$672.00K
derived: sum of 2 quarters · filed 2022-11-03
-$695.00K
10-Q · filed 2022-11-03
$215.00K
derived: sum of 4 quarters · filed 2023-03-21
2021-06-30-$569.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04
-$592.00K
10-Q · filed 2022-08-04
$318.00K
derived: sum of 3 quarters · filed 2023-03-21
$650.00K
derived: sum of 4 quarters · filed 2023-03-21
2021-03-31-$23.00K
10-Q · filed 2022-05-12
$887.00K
derived: sum of 2 quarters · filed 2023-03-21
$1.22M
derived: sum of 3 quarters · filed 2023-03-21
$1.81M
derived: sum of 4 quarters · filed 2023-03-21
2020-12-31$910.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-21
$1.24M
derived: sum of 2 quarters · filed 2023-03-21
$1.83M
derived: sum of 3 quarters · filed 2023-03-21
$1.03M
10-K · filed 2023-03-21
2020-09-30$332.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04
$921.00K
derived: sum of 2 quarters · filed 2021-11-04
$121.00K
10-Q · filed 2021-11-04
$500.00K
derived: sum of 4 quarters · filed 2022-03-17
2020-06-30$589.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-03
-$211.00K
10-Q · filed 2021-08-03
$168.00K
derived: sum of 3 quarters · filed 2022-03-17
-$1.26M
derived: sum of 4 quarters · filed 2022-03-17
2020-03-31-$800.00K
10-Q · filed 2021-05-06
-$421.00K
derived: sum of 2 quarters · filed 2022-03-17
-$1.85M
derived: sum of 3 quarters · filed 2022-03-17
-$4.88M
derived: sum of 4 quarters · filed 2022-03-17
2019-12-31$379.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17
-$1.05M
derived: sum of 2 quarters · filed 2022-03-17
-$4.08M
derived: sum of 3 quarters · filed 2022-03-17
-$2.75M
10-K · filed 2022-03-17
2019-09-30-$1.43M
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05
-$4.46M
derived: sum of 2 quarters · filed 2020-11-05
-$3.13M
10-Q · filed 2020-11-05
-$2.03M
derived: sum of 4 quarters · filed 2021-03-19
2019-06-30-$3.03M
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-04
-$1.70M
10-Q · filed 2020-08-04
-$604.00K
derived: sum of 3 quarters · filed 2021-03-19
$210.00K
derived: sum of 4 quarters · filed 2021-03-19
2019-03-31$1.33M
10-Q · filed 2020-05-07
$2.43M
derived: sum of 2 quarters · filed 2021-03-19
$3.24M
derived: sum of 3 quarters · filed 2021-03-19
$3.20M
derived: sum of 4 quarters · filed 2021-03-19
2018-12-31$1.10M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-19
$1.91M
derived: sum of 2 quarters · filed 2021-03-19
$1.87M
derived: sum of 3 quarters · filed 2021-03-19
$1.31M
10-K · filed 2021-03-19
-$1.34M
10-K · filed 2019-03-11
2018-09-30$814.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07
$772.00K
derived: sum of 2 quarters · filed 2019-11-07
$209.00K
10-Q · filed 2019-11-07
$270.00K
10-Q · filed 2018-11-09
-$3.30M
derived: sum of 4 quarters · filed 2020-03-12
2018-06-30-$42.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07
-$605.00K
10-Q · filed 2019-08-07
$257.00K
10-Q · filed 2018-08-13
-$4.12M
derived: sum of 3 quarters · filed 2020-03-12
-$1.21M
derived: sum of 4 quarters · filed 2020-03-12
2018-03-31-$563.00K
10-Q · filed 2019-05-15
-$788.00K
10-Q · filed 2018-05-10
-$4.07M
derived: sum of 2 quarters · filed 2020-03-12
-$1.17M
derived: sum of 3 quarters · filed 2020-03-12
-$3.07M
derived: sum of 4 quarters · filed 2020-03-12
2017-12-31-$3.51M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12
-$606.00K
derived: sum of 2 quarters · filed 2020-03-12
-$2.51M
derived: sum of 3 quarters · filed 2020-03-12
-$1.17M
10-K · filed 2020-03-12
$182.00K
10-K · filed 2019-03-11
2017-09-30$2.90M
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09
$1.00M
derived: sum of 2 quarters · filed 2018-11-09
$2.34M
10-Q · filed 2018-11-09
2017-06-30-$1.90M
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-13
-$563.00K
10-Q · filed 2018-08-13
2017-03-31$1.34M
10-Q · filed 2018-05-10
2016-12-31$1.26M
10-K · filed 2019-03-11

Similar stocks

Stock NameCountryMarket CapPE Ratio
Inhibikase Therapeutics, Inc. (IKT)United States$0.296B-4.44
SAB Biotherapeutics, Inc. (SABS)United States$0.306B-25.49
Century Therapeutics, Inc. (IPSC)United States$0.306B-4.02
Liminatus Pharma, Inc. (LIMN)United States$0.282B
FATE THERAPEUTICS INC (FATE)United States$0.280B-2.51
Lexeo Therapeutics, Inc. (LXEO)United States$0.278B-4.19
PALISADE BIO, INC. (PALI)United States$0.275B-11.41
Invivyd, Inc. (IVVD)United States$0.270B-2.42
SUTRO BIOPHARMA, INC. (STRO)United States$0.260B-3.05
Ocugen, Inc. (OCGN)United States$0.343B-6.34